A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age
Authors:
Open Access
- 1 April 2022
- Vol. 40 (15) , 2352-2361
Abstract
No abstract availableKeywords
Funding Information
- Bill & Melinda Gates Foundation
This publication has 33 references indexed in Scilit:
- Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis VaccinationPLOS ONE, 2016
- Antibody Responses After Primary Immunization in Infants Born to Women Receiving a Pertussis-containing Vaccine During Pregnancy: Single Arm Observational Study With a Historical ComparatorClinical Infectious Diseases, 2015
- Pertussis Across the GlobeThe Pediatric Infectious Disease Journal, 2015
- Pertussis vaccines: WHO position paper - September 2015.2015
- Effectiveness of maternal pertussis vaccination in England: an observational studyThe Lancet, 2014
- Immunization policy development in Thailand: The role of the Advisory Committee on Immunization PracticeVaccine, 2010
- Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19–64 years of ageVaccine, 2009
- Correlation between Pertussis Toxin IgG Antibodies in Postvaccination Sera and Subsequent Protection against PertussisThe Journal of Infectious Diseases, 2000
- The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodiesVaccine, 1996
- A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against PertussisNew England Journal of Medicine, 1996